A Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs T cell replacement therapy (Primary)
- Indications Haematological malignancies; Lymphoid leukaemia
- Focus Adverse reactions
- 19 Mar 2019 Biomarkers information updated
- 24 Feb 2012 Actual initiation date (1 Jan 2012) added as reported by ClinicalTrials.gov.
- 24 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.